Comparative evaluation of the UMIC Colistine kit to assess MIC of colistin of gram-negative rods.


Journal

BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981

Informations de publication

Date de publication:
18 03 2019
Historique:
received: 25 10 2017
accepted: 21 02 2019
entrez: 20 3 2019
pubmed: 20 3 2019
medline: 12 2 2020
Statut: epublish

Résumé

The recent description of the first plasmid-mediated colistin-resistant gene mcr-1, conferring transferable and low-level resistance to colistin, raised concern about the need to implement a rapid and reliable screening method to detect colistin-resistant clinical isolates. The only valid method to assess the MIC of colistin is the broth microdilution according to the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. UMIC Colistine is a ready-to-use broth microdilution kit developed to easily assess colistin MIC by proposing unitary polystyrene strips containing 11 concentrations of dehydrated colistin. Here, we evaluated the UMIC Colistine kit on 235 Gram-negative rods (176 Enterobacterales, including 70 harboring a mcr gene, and 59 non-fermentative), through comparison to the reference broth microdilution method prepared in accordance with EN ISO 20776-1:2006 standard. Reproducibility of the UMIC Colistine was assayed with the three recommended quality control strains E. coli ATCC 25922, E. coli NCTC 13846 (mcr-1 positive), and P. aeruginosa ATCC 27853, as for stability testing. Categorical agreement was 100% with 63.4% (n = 149) of colistin-resistant strains, and 36.6% (n = 86) of colistin-susceptible strains with both methods (S ≤ 2 μg/mL and R > 2 μg/mL). No major error or very major error was reported. Essential agreement was 94.0% (n = 221), and 100% for detection of colistin-resistant strains as compared to the reference method. Pearson's correlation between UMIC Colistine and the reference method was 0.98. Reproducibility of the UMIC Colistine system was 97.8% with MICs of the quality control strains within the target ranges. However, some isolates had lower MIC with UMIC Colistine, but that did not change their categorization as colistin-susceptible, and this phenomenon should be further explored. The UMIC Colistine kit is an easy to perform unitary device that showed excellent results when compared to the reference method. The UMIC Colistine system is a rapid and reliable broth microdilution method that is suitable to assess the colistin MIC of clinical isolates in clinical microbiology laboratories.

Sections du résumé

BACKGROUND
The recent description of the first plasmid-mediated colistin-resistant gene mcr-1, conferring transferable and low-level resistance to colistin, raised concern about the need to implement a rapid and reliable screening method to detect colistin-resistant clinical isolates. The only valid method to assess the MIC of colistin is the broth microdilution according to the joint CLSI-EUCAST Polymyxin Breakpoints Working Group. UMIC Colistine is a ready-to-use broth microdilution kit developed to easily assess colistin MIC by proposing unitary polystyrene strips containing 11 concentrations of dehydrated colistin. Here, we evaluated the UMIC Colistine kit on 235 Gram-negative rods (176 Enterobacterales, including 70 harboring a mcr gene, and 59 non-fermentative), through comparison to the reference broth microdilution method prepared in accordance with EN ISO 20776-1:2006 standard. Reproducibility of the UMIC Colistine was assayed with the three recommended quality control strains E. coli ATCC 25922, E. coli NCTC 13846 (mcr-1 positive), and P. aeruginosa ATCC 27853, as for stability testing.
RESULTS
Categorical agreement was 100% with 63.4% (n = 149) of colistin-resistant strains, and 36.6% (n = 86) of colistin-susceptible strains with both methods (S ≤ 2 μg/mL and R > 2 μg/mL). No major error or very major error was reported. Essential agreement was 94.0% (n = 221), and 100% for detection of colistin-resistant strains as compared to the reference method. Pearson's correlation between UMIC Colistine and the reference method was 0.98. Reproducibility of the UMIC Colistine system was 97.8% with MICs of the quality control strains within the target ranges. However, some isolates had lower MIC with UMIC Colistine, but that did not change their categorization as colistin-susceptible, and this phenomenon should be further explored.
CONCLUSIONS
The UMIC Colistine kit is an easy to perform unitary device that showed excellent results when compared to the reference method. The UMIC Colistine system is a rapid and reliable broth microdilution method that is suitable to assess the colistin MIC of clinical isolates in clinical microbiology laboratories.

Identifiants

pubmed: 30885126
doi: 10.1186/s12866-019-1424-8
pii: 10.1186/s12866-019-1424-8
pmc: PMC6421643
doi:

Substances chimiques

Anti-Bacterial Agents 0
Reagent Kits, Diagnostic 0
Colistin Z67X93HJG1

Types de publication

Comparative Study Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

60

Références

Microbiologyopen. 2019 Apr;8(4):e00682
pubmed: 29974640
J Antimicrob Chemother. 2018 Jul 1;73(7):1791-1795
pubmed: 29912417
J Antimicrob Chemother. 2018 Oct 1;73(10):2904
pubmed: 30053008
J Antimicrob Chemother. 2018 May 1;73(5):1272-1278
pubmed: 29481600
Int J Infect Dis. 2017 Jan;54:77-84
pubmed: 27915108
Int J Infect Dis. 2014 Apr;21:21-3
pubmed: 24560830
J Infect Dis. 2011 Oct 1;204(7):1147-8
pubmed: 21881133
Expert Rev Anti Infect Ther. 2012 Aug;10(8):917-34
pubmed: 23030331
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172
Int J Antimicrob Agents. 2012 Dec;40(6):566-7
pubmed: 22951226
BMC Microbiol. 2017 Nov 23;17(1):220
pubmed: 29169321
Clin Microbiol Rev. 2015 Jan;28(1):191-207
pubmed: 25567227
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28264851
J Glob Antimicrob Resist. 2017 Sep;10:35-36
pubmed: 28576739
Clin Microbiol Infect. 2018 Aug;24(8):865-870
pubmed: 29221995
mBio. 2017 Jun 27;8(3):
pubmed: 28655818
Euro Surveill. 2016 Jul 7;21(27):
pubmed: 27416987
Clin Microbiol Rev. 2017 Apr;30(2):557-596
pubmed: 28275006
Emerg Microbes Infect. 2018 Jul 4;7(1):122
pubmed: 29970891
J Antimicrob Chemother. 2017 Dec 1;72(12):3317-3324
pubmed: 28962028
Euro Surveill. 2017 Aug 3;22(31):
pubmed: 28797329
Int J Antimicrob Agents. 2016 Dec;48(6):583-591
pubmed: 27524102
Microb Drug Resist. 2019 Mar;25(2):233-240
pubmed: 30142027

Auteurs

Lucie Bardet (L)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Liliane Okdah (L)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Stéphanie Le Page (S)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Sophie Alexandra Baron (SA)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Jean-Marc Rolain (JM)

Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France. jean-marc.rolain@univ.amu.fr.
IHU-Méditerranée Infection, Marseille, France. jean-marc.rolain@univ.amu.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH